Cargando…
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
BACKGROUND: PG545 is a heparan sulfate (HS) mimetic that inhibits tumour angiogenesis by sequestering angiogenic growth factors in the extracellular matrix (ECM), thus limiting subsequent binding to receptors. Importantly, PG545 also inhibits heparanase, the only endoglycosidase which cleaves HS cha...
Autores principales: | Dredge, K, Hammond, E, Handley, P, Gonda, T J, Smith, M T, Vincent, C, Brandt, R, Ferro, V, Bytheway, I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049593/ https://www.ncbi.nlm.nih.gov/pubmed/21285983 http://dx.doi.org/10.1038/bjc.2011.11 |
Ejemplares similares
-
Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues()
por: Hammond, Edward, et al.
Publicado: (2013) -
PG545, a Heparan Sulfate Mimetic, Reduces Heparanase Expression In Vivo, Blocks Spontaneous Metastases and Enhances Overall Survival in the 4T1 Breast Carcinoma Model
por: Hammond, Edward, et al.
Publicado: (2012) -
Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545
por: Abassi, Zaid, et al.
Publicado: (2017) -
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours
por: Dredge, Keith, et al.
Publicado: (2018) -
Structural Insights into Pixatimod (PG545) Inhibition of Heparanase, a Key Enzyme in Cancer and Viral Infections
por: Chhabra, Mohit, et al.
Publicado: (2022)